Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 3/20 | 0.32 |
| ▸ | BPTF | Q12830 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269182 | 0.90 | TP53 (0.38) | TP53LMNAENPP2POLBKMT2A | |
| SCHEMBL1268426 | 0.87 | LMNA (0.37) | TP53LMNAMGLLPOLB | |
| SCHEMBL1269350 | 0.80 | PROKR1 (0.38) | TP53LMNAGRM4HPGDPOLB | |
| SCHEMBL1268804 | 0.77 | PROKR1 (0.36) | TP53LMNAPOLB | |
| SCHEMBL1269328 | 0.77 | HTR6 (0.36) | TP53LMNAPOLBMEN1KMT2A | |
| SCHEMBL1268280 | 0.77 | PROKR1 (0.39) | TP53LMNAPOLB | |
| SCHEMBL1269223 | 0.76 | HTR6 (0.41) | — | |
| SCHEMBL1269325 | 0.76 | SMN1; SMN2 (0.40) | LMNAPOLBMEN1KMT2A | |
| SCHEMBL1269577 | 0.72 | GRM5 (0.33) | — | |
| SCHEMBL1269243 | 0.72 | MCHR1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | GSK3B, GSK3A, GSKIP | TP53 1224/4885LMNA 1199/4885GRM4 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.